Conversely, eliminating IL-2 expression using tacrolimus (FK506), an inhibitor of calcineurin (29), also diminished the difference in tumor growth (Figure 4K and Supplemental Figure 4K), as well as the IFN production by WT and Gsdmd–/– lymphocytes, including CD4+ T, CD8+ T, and NK cells (Figure 4L and Supplemental Figure 4L). The gene discussed is IL2; the disease is neoplasm.